These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 38136402)

  • 1. Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance.
    Yao L; Wang Q; Ma W
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the landscape of drug resistance in gastrointestinal cancer immunotherapy: A review.
    Yao N; Li W; Duan N; Xu G; Yu G; Qu J
    Medicine (Baltimore); 2024 Jan; 103(2):e36957. PubMed ID: 38215151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy revolutionizing brain metastatic cancer treatment: personalized strategies for transformative outcomes.
    Li T; Sun S; Li Y; Zhang Y; Wei L
    Front Immunol; 2024; 15():1418580. PubMed ID: 39136027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies.
    Chyuan IT; Chu CL; Hsu PN
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.
    Blair AB; Murphy A
    Curr Probl Cancer; 2018; 42(1):49-58. PubMed ID: 29501212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in lung cancer research: unravelling the future of treatment.
    Bertolaccini L; Casiraghi M; Uslenghi C; Maiorca S; Spaggiari L
    Updates Surg; 2024 Oct; 76(6):2129-2140. PubMed ID: 38581618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer.
    Liu D; Che X; Wang X; Ma C; Wu G
    Pharmaceuticals (Basel); 2023 Sep; 16(10):. PubMed ID: 37895855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapies: advances and bottlenecks.
    Rui R; Zhou L; He S
    Front Immunol; 2023; 14():1212476. PubMed ID: 37691932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment.
    Zhang J; Tavakoli H; Ma L; Li X; Han L; Li X
    Adv Drug Deliv Rev; 2022 Aug; 187():114365. PubMed ID: 35667465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.
    Xu S; Wang C; Yang L; Wu J; Li M; Xiao P; Xu Z; Xu Y; Wang K
    Front Immunol; 2023; 14():1199631. PubMed ID: 37313405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular therapeutics in pancreas cancer.
    Narayanan V; Weekes CD
    World J Gastrointest Oncol; 2016 Apr; 8(4):366-79. PubMed ID: 27096032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomimetic nanotechnology for cancer immunotherapy: State of the art and future perspective.
    Sarkar Lotfabadi A; Abadi B; Rezaei N
    Int J Pharm; 2024 Apr; 654():123923. PubMed ID: 38403091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cancer metabolism on therapy resistance - Clinical implications.
    Gonçalves AC; Richiardone E; Jorge J; Polónia B; Xavier CPR; Salaroglio IC; Riganti C; Vasconcelos MH; Corbet C; Sarmento-Ribeiro AB
    Drug Resist Updat; 2021 Dec; 59():100797. PubMed ID: 34955385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-host colluding through erythroid progenitor cells: Mechanisms and opportunities.
    Wang YY; Wu ZZ; Huang CF; Sun ZJ
    Cancer Lett; 2023 Jun; 563():216193. PubMed ID: 37088326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
    Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
    Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Immuno-oncology Targets and Resistance Mechanisms.
    Tokaz MC; Baik CS; Houghton AM; Tseng D
    Curr Treat Options Oncol; 2022 Sep; 23(9):1201-1218. PubMed ID: 35980521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.